Redcare Pharmacy NV RDC.DE
Composite 36/100; the shares have moved about 63% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 14/100 — a strong mark against it.
Momentum ranks 54/100 — a slight point in its favour.
Quality ranks 14/100 — a strong mark against it. Valuation ranks 27/100 — a moderate mark against it. Growth ranks 45/100 — a slight mark against it.
What the company does Redcare Pharmacy NV operates an online pharmacy across seven European markets, selling prescription and over-the-counter medicines, beauty products, and food supplements under the Redcare brand.
Key financials Redcare’s profitability metrics remain weak: ROE -8%, ROA -1%, and net margin -1.2%. Revenue grew 18% year-over-year, but EPS growth was flat. Leverage is elevated (Debt/Equity 0.75) with a high EV/EBITDA of 33.27 and negative free cash flow yield of -9%.
Stock health Momentum is mixed: +43% over 3 months, +16% over 6 months, but -30% over 12 months and -34% below its 52-week high. The RSI stands at 60, indicating moderate bullish momentum.
Price vs fair value The stock trades at a discount of 21.50% versus the 12-month analyst target of 84.20. - Analysts cite revenue growth guidance raised in Q2 2026 earnings call (GuruFocus.com). - Sideravia scores the company as “Poor quality, fairly valued” with an overall score of 41.7. - Forward P/E of 625x reflects high expectations embedded in the current price. - Piotroski F-Score of 4/9 and Altman Z of 3.60 suggest elevated financial risk.
Looking forward Analysts expect continued revenue growth, but profitability and cash flow remain key concerns. The high valuation multiple (EV/EBITDA 33.27) hinges on sustained execution in competitive European e-commerce markets.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.